IFNA1 and systemic lupus erythematosus: A number of therapeutics have been developed to target type I IFN in SLE, including monoclonal antibodies against IFN-α (Merrill et al., 2011; Kalunian et al., 2012; McBride et al., 2012), as well as a vaccination strategy aimed at inducing antibodies against IFN-α (Lauwerys et al., 2013).